SANTA CLARA, Calif., July 12 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX) today announced that it has teamed with Drs. Hans Skovgaard
Poulsen and Jens Benn Sorensen from the Department of Oncology at the
Rigshospitalet University of Copenhagen, Denmark, to optimize and validate a
new blood test for the early diagnosis of cancer metastasis.  The initial
study will focus on patients suffering from colorectal carcinomas (tumors) of
all stages with emphasis on the early stages when the tumor is still localized
and a metastasis predictor is of extreme importance.
    The annual incidence of colorectal cancer in the United States, Europe and
Japan is approximately 400,000 cases; of these about 30 percent will have
advanced disease at the time of diagnosis.  Cure rates of colorectal cancer at
an advanced stage are very low due to the high metastatic potential of this
type of carcinoma.  Therefore, the detection of patients at risk for
development of metastases early in the progression of the disease is of
critical importance since these patients will benefit best from systemic
cytostatic treatment, such as chemotherapy.  Applied Imaging believes that
this simple procedure will help the physician better assess the stage of the
disease and provide the patient with the appropriate treatment.
    Applied Imaging CEO Dr. Jack Goldstein stated, "Rigshospitalet University
in Copenhagen is one of the premier cancer centers in Europe with access to a
large pool of patients that will drive this study to completion in a relative
short period of time.  This blood test is a key component of Applied Imaging
long term strategy to become the leading provider of instrumentation and
reagents for the clinical and research cancer markets".
    Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories for the analysis of chromosomes in cancer and prenatal disorders.
The Company is expanding its efforts in scanning and imaging applications in
the cancer pathology field, as well as providing key reagents in this area.
Applied Imaging has installed over 1800 systems in 800 laboratories in more
than 35 countries.

    This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the Company's future financial performance as well as its research
and development and product development efforts.  Forward-looking statements
address matters that are subject to a number of risks and uncertainties,
including the uncertainty of clinical studies and regulatory approvals.
Actual results could differ materially from those projected in the forward-
looking statement as a result of a number of factors including the failure of
the Company to successfully develop and commercialize its micrometastasis or
genetic instrument business, and other such factors as set forth in the
Company's form 10k for the year ended December 31, 1999 as filed with the
Securities and Exchange Commission.

    For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX.

Link to this page: